{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:03:40Z","timestamp":1769043820121,"version":"3.49.0"},"reference-count":59,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2020,4,22]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>Gene therapy (GT) has tremendous potential for the treatment of neurological disorders to transform patient care. The successful application of virus-mediated GT to treat spinal muscular atrophy is a significant milestone, serving to accelerate similar progress in a spectrum of neurological conditions, with more than 50 clinical trials currently underway, across neurodevelopmental, neurodegenerative, muscular dystrophy, epilepsy, chronic pain and neoplastic diseases. This review provides an overview of the key features of virus-mediated GT, paradigms of delivery and dosing, potential risks and highlights ongoing research to optimise safe and effective delivery of vectors into the nervous system. Examples of the application of GT in various neurological diseases alongside clinical development challenges will be presented. As the development and translation of GTs gain pace, success can only ultimately be realised for patients following implementation in the health system. The challenges and controversies of daunting costs, ethics, early diagnosis and health system readiness will require innovative pricing schemes, regulatory policies, education and organisation of a skilled workforce to deliver of high-quality care in clinical practice as we prepare for advanced therapeutics in neurology.<\/jats:p>","DOI":"10.1136\/jnnp-2019-322327","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T21:20:07Z","timestamp":1591392007000},"page":"849-860","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Great expectations: virus-mediated gene therapy in neurological disorders"],"prefix":"10.1136","volume":"91","clinical-trial-number":[{"clinical-trial-number":"nct03505099","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03306277","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Didu","family":"Kariyawasam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian E","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4472-0902","authenticated-orcid":false,"given":"Michelle Anne","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"2024120318500638000_91.8.849.1","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146683","article-title":"Gene therapies for axonal neuropathies: available strategies, successes to date, and what to target next","volume":"1732","author":"Morelli","year":"2020","journal-title":"Brain Res"},{"key":"2024120318500638000_91.8.849.2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/nat.2017.0715","article-title":"Journey of siRNA: clinical developments and targeted delivery","volume":"28","author":"Nikam","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"2024120318500638000_91.8.849.3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184388","article-title":"Gene therapy for ALS-A perspective","volume":"20","author":"Cappella","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2024120318500638000_91.8.849.4","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","article-title":"Results from a phase I safety trial of hAADC gene therapy for Parkinson disease","volume":"70","author":"Eberling","year":"2008","journal-title":"Neurology"},{"key":"2024120318500638000_91.8.849.5","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/mt.2010.135","article-title":"A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease","volume":"18","author":"Muramatsu","year":"2010","journal-title":"Mol Ther"},{"key":"2024120318500638000_91.8.849.6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/hum.2011.220","article-title":"Long-Term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease","volume":"23","author":"Mittermeyer","year":"2012","journal-title":"Hum Gene Ther"},{"key":"2024120318500638000_91.8.849.7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","article-title":"Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial","volume":"1","author":"Chien","year":"2017","journal-title":"Lancet Child Adolesc Health"},{"key":"2024120318500638000_91.8.849.8","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-Term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"Lancet"},{"key":"2024120318500638000_91.8.849.9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.omtm.2019.07.002","article-title":"Gene Therapy for Parkinson's Disease: Preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis","volume":"14","author":"Badin","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024120318500638000_91.8.849.10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1212\/WNL.0000000000003554","article-title":"Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy","volume":"88","author":"Richard","year":"2017","journal-title":"Neurology"},{"key":"2024120318500638000_91.8.849.11","doi-asserted-by":"crossref","first-page":"709-715","DOI":"10.1111\/ene.14131","article-title":"Value of insoluble PABPN1 accumulation in the diagnosis of oculopharyngeal muscular dystrophy","volume":"27","author":"Galimberti","year":"2020","journal-title":"Eur J Neurol"},{"key":"2024120318500638000_91.8.849.12","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14848","article-title":"Pabpn1 gene therapy for oculopharyngeal muscular dystrophy","volume":"8","author":"Malerba","year":"2017","journal-title":"Nat Commun"},{"key":"2024120318500638000_91.8.849.13","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1161\/CIRCRESAHA.116.309727","article-title":"Gene editing with CRISPR\/Cas9 RNA-directed nuclease","volume":"120","author":"Doetschman","year":"2017","journal-title":"Circ Res"},{"key":"2024120318500638000_91.8.849.14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020500","article-title":"Genome editing for mucopolysaccharidoses","volume":"21","author":"Poletto","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2024120318500638000_91.8.849.15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nbt.3852","article-title":"Genome-Wide target specificities of CRISPR RNA-guided programmable deaminases","volume":"35","author":"Kim","year":"2017","journal-title":"Nat Biotechnol"},{"key":"2024120318500638000_91.8.849.16","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1523\/JNEUROSCI.2016-16.2016","article-title":"Vectored intracerebral immunization with the anti-Tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice","volume":"36","author":"Liu","year":"2016","journal-title":"J Neurosci"},{"key":"2024120318500638000_91.8.849.17","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S1353-8020(08)70052-X","article-title":"Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point","volume":"13 Suppl 3","author":"Bartus","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"2024120318500638000_91.8.849.18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-017-0052-4","article-title":"Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I","volume":"40","author":"Penati","year":"2017","journal-title":"J Inherit Metab Dis"},{"key":"2024120318500638000_91.8.849.19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"2024120318500638000_91.8.849.20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-Associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"2024120318500638000_91.8.849.21","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-Complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther"},{"key":"2024120318500638000_91.8.849.22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mt.2009.280","article-title":"Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus","volume":"18","author":"Hirsch","year":"2010","journal-title":"Mol Ther"},{"key":"2024120318500638000_91.8.849.23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nm1439","article-title":"Systemic delivery of rAAV6-microdystrophin preserves muscle function and extends lifespan in a murine model of severe muscular dystrophy","volume":"12","author":"Gregorevic","year":"2006","journal-title":"J Nature medicine"},{"key":"2024120318500638000_91.8.849.24","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.1073\/pnas.97.12.6716","article-title":"Trans-Splicing vectors expand the utility of adeno-associated virus for gene therapy","volume":"97","author":"Yan","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024120318500638000_91.8.849.25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"2024120318500638000_91.8.849.26","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.nmd.2017.06.412","article-title":"AVXS-101 phase 1 gene therapy clinical trial in SMA type 1: end-of-Study event free survival and achievement of developmental milestones","volume":"27","author":"Mendell","year":"2017","journal-title":"Neuromuscular Disorders"},{"key":"2024120318500638000_91.8.849.27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"key":"2024120318500638000_91.8.849.28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/humc.2017.010","article-title":"Persistent expression of Dopamine-Synthesizing enzymes 15 years after gene transfer in a primate model of Parkinson's disease","volume":"28","author":"Sehara","year":"2017","journal-title":"Hum Gene Ther Clin Dev"},{"key":"2024120318500638000_91.8.849.29","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1523\/JNEUROSCI.6000-11.2012","article-title":"A mouse model for MeCP2 duplication syndrome: MeCP2 overexpression impairs learning and memory and synaptic transmission","volume":"32","author":"Na","year":"2012","journal-title":"J Neurosci"},{"key":"2024120318500638000_91.8.849.30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"2024120318500638000_91.8.849.31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuropharm.2017.05.029","article-title":"Gene therapy and editing: novel potential treatments for neuronal channelopathies","volume":"132","author":"Wykes","year":"2018","journal-title":"Neuropharmacology"},{"key":"2024120318500638000_91.8.849.32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-Dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2024120318500638000_91.8.849.33","first-page":"249","article-title":"13 Lentivirus-Based genetic manipulations in neurons in vivo","volume":"27","author":"Osten","year":"2006","journal-title":"The dynamic synapse: molecular methods in ionotropic receptor biology"},{"key":"2024120318500638000_91.8.849.34","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"2024120318500638000_91.8.849.35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1006\/mthe.2000.0213","article-title":"A tumultuous year for gene therapy","volume":"2","author":"Verma","year":"2000","journal-title":"Mol Ther"},{"key":"2024120318500638000_91.8.849.36","doi-asserted-by":"crossref","unstructured":"pp. Goins WF , Huang S , Hall B , et al . Engineering HSV-1 vectors for gene therapy. Herpes Simplex Virus. Springer 2020:73\u201390.","DOI":"10.1007\/978-1-4939-9814-2_4"},{"key":"2024120318500638000_91.8.849.37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1074549","article-title":"Subthalamic GAD gene therapy in a Parkinson's disease rat model","volume":"298","author":"Luo","year":"2002","journal-title":"Science"},{"key":"2024120318500638000_91.8.849.38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/hum.2011.200","article-title":"Adeno-Associated virus serotype 9 transduction in the central nervous system of nonhuman primates","volume":"23","author":"Samaranch","year":"2012","journal-title":"Hum Gene Ther"},{"key":"2024120318500638000_91.8.849.39","unstructured":"Analytics F . NOVARTIS AG CHF0. 50 (REGD)(0QLR)."},{"key":"2024120318500638000_91.8.849.40","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1399-0004.2009.01324.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study","volume":"77","author":"McGill","year":"2010","journal-title":"Clin Genet"},{"key":"2024120318500638000_91.8.849.41","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"2024120318500638000_91.8.849.42","unstructured":"National Academies of Sciences E and Medicine. Human genome editing: science, ethics, and governance. National Academies Press 2017."},{"key":"2024120318500638000_91.8.849.43","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene therapy leaves a vicious cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front Oncol"},{"key":"2024120318500638000_91.8.849.44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3233\/JHD-160215","article-title":"Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140\/Q140 Mice","volume":"5","author":"Keeler","year":"2016","journal-title":"J Huntingtons Dis"},{"key":"2024120318500638000_91.8.849.45","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/mds.27595","article-title":"Sample enrichment for clinical trials to show delay of onset in Huntington disease","volume":"34","author":"Paulsen","year":"2019","journal-title":"Mov Disord"},{"key":"2024120318500638000_91.8.849.46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7108","article-title":"Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease","volume":"10","author":"Byrne","year":"2018","journal-title":"Sci Transl Med"},{"key":"2024120318500638000_91.8.849.47","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jnnp-2017-317412","article-title":"Nusinersen for SMA: expanded access programme","volume":"89","author":"Farrar","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024120318500638000_91.8.849.48","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-017-0475-4","article-title":"Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic","volume":"9","author":"Nicol","year":"2017","journal-title":"Genome Med"},{"key":"2024120318500638000_91.8.849.49","article-title":"Health ministers condemn Novartis lottery for Zolgensma","volume":"368","author":"Dyer","year":"2020","journal-title":"the world\u2019s most expensive drug"},{"key":"2024120318500638000_91.8.849.50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.nbd.2015.11.014","article-title":"Translational approach for gene therapy in epilepsy: model system and unilateral overexpression of neuropeptide Y and Y2 receptors","volume":"86","author":"Ledri","year":"2016","journal-title":"Neurobiol Dis"},{"key":"2024120318500638000_91.8.849.51","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1528-1167.2010.02947.x","article-title":"Adenosine kinase as a target for therapeutic antisense strategies in epilepsy","volume":"52","author":"Theofilas","year":"2011","journal-title":"Epilepsia"},{"key":"2024120318500638000_91.8.849.52","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1528-1167.2010.02672.x","article-title":"Inhibitory RNA in epilepsy: research tools and therapeutic perspectives","volume":"51","author":"Boison","year":"2010","journal-title":"Epilepsia"},{"key":"2024120318500638000_91.8.849.53","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1152\/physrev.00017.2004","article-title":"Ion channel development, spontaneous activity, and activity-dependent development in nerve and muscle cells","volume":"85","author":"Moody","year":"2005","journal-title":"Physiol Rev"},{"key":"2024120318500638000_91.8.849.54","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/ana.20483","article-title":"Gene transfer of glutamic acid decarboxylase reduces neuropathic pain","volume":"57","author":"Hao","year":"2005","journal-title":"Ann Neurol"},{"key":"2024120318500638000_91.8.849.55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbi.2017.11.004","article-title":"Effects of spinal non-viral interleukin-10 gene therapy formulated with D-mannose in neuropathic interleukin-10 deficient mice: behavioral characterization, mRNA and protein analysis in pain relevant tissues","volume":"69","author":"Vanderwall","year":"2018","journal-title":"Brain Behav Immun"},{"key":"2024120318500638000_91.8.849.56","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/jnnp-2012-302946","article-title":"The art of gene therapy for glioma: a review of the challenging road to the bedside","volume":"84","author":"Tobias","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024120318500638000_91.8.849.57","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.gt.3301664","article-title":"The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study","volume":"9","author":"Papanastassiou","year":"2002","journal-title":"Gene Ther"},{"key":"2024120318500638000_91.8.849.58","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","article-title":"A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting","volume":"10","author":"Chiocca","year":"2004","journal-title":"Mol Ther"},{"key":"2024120318500638000_91.8.849.59","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1525-0016(03)00100-X","article-title":"Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir","volume":"7","author":"Smitt","year":"2003","journal-title":"Mol Ther"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2019-322327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T02:53:44Z","timestamp":1733280824000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2019-322327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,7,20]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/jnnp-2019-322327"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2019-322327","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}